Headlines

Go To Pro Hockey Rumors
Go To Hoops Rumors

Chris Sale

Latest On Braves’ Deadline Approach

By | at

The Braves have been in a downward spiral for much of the season. They’ve shown signs of life at various points, but those brief flashes were quickly stamped out by repeated injuries to star players. Atlanta lost Reynaldo Lopez to arthroscopic shoulder surgery in mid-April and was without both Spencer Strider and Ronald Acuña Jr. to begin the season. That All-Star duo has since returned, but over the past month the Braves have lost Chris Sale (fractured ribs), Spencer Schwellenbach (fractured elbow) and AJ Smith-Shawver (Tommy John surgery). Setup man Joe Jimenez underwent knee surgery in the offseason and is likely to miss the entire year as well.

On top of that brutal slate of pitching injuries, the Braves have seen several key players take major steps back in performance. Ozzie Albies and Michael Harris II have been two of baseball’s least-productive hitters. Closer Raisel Iglesias, fresh off a career-best year in 2024, is having a career-worst season in 2025 — although he’s recently rattled off 10 2/3 shutout innings with a 15-to-1 K/BB ratio, so perhaps he’s coming around. Austin Riley and Marcell Ozuna are both hitting better than the league-average hitter but worse than their career norms. Jurickson Profar missed 80 games due to a PED suspension.

The result is a 40-52 team that sits 13.5 games out of the division lead and 10 games back in the Wild Card hunt. FanGraphs gives Atlanta a 3.7% chance of making the postseason, which feels charitable for a club that presently has three healthy starters (Strider, Grant Holmes and Bryce Elder). The Braves rushed prospect Didier Fuentes to the majors just three days after his 20th birthday and despite having just 26 1/3 innings above A-ball under his belt. Predictably, it has not gone well (13.85 ERA in four starts).

The stage is set for Atlanta to operate in an unfamiliar manner this deadline, playing the role of a seller. President of baseball operations Alex Anthopoulos emphatically denounced the notion of even considering a trade of Sale last month, just prior to the left-hander’s injury. Anthopoulos called any speculation regarding a Sale trade “completely ridiculous” in an appearance on 680 The Fan in Atlanta.

“I never make definitive statements unless I’m going to stick to them,” he said at the time. “Once you make definitive statements and then you go back on them, you’re a liar and you’re done. [A trade of Sale] Will. Not. Happen. Bold, italicize it, caps.”

Even with the tumult that’s followed those statements — which predated not only Sale’s injury but also the Schwellenbach injury — the thinking doesn’t appear to have changed. Robert Murray of FanSided reports that the Braves have not discussed Sale in any trade talks and, furthermore, do not intend to listen on any player who’s controlled beyond the 2025 season.

[Related: Atlanta Braves Trade Deadline Outlook]

If that’s indeed the case, the Braves will be in for a quiet deadline. Atlanta only has three true free agents at season’s end: Iglesias, Ozuna and right-hander Rafael Montero. Any of the three could hold appeal on the market.

Iglesias, as noted, has had an uneven season but turned a corner of late. He’s sitting on a 4.67 ERA overall, but that’s a function of the 35-year-old’s 6.75 ERA through early June. Even as Iglesias struggled to those ugly results, however, he posted strong strikeout and walk rates. He was dogged by a .348 average on balls in play and a sky-high 21.9% homer-to-flyball rate along the way, but metrics like SIERA (3.34) still pegged him as a quality reliever and hinted at positive regression. Iglesias hasn’t markedly changed up his pitch selection, but he’s now missing far more bats in the zone and has recorded a colossal 20.7% swinging-strike rate over the course of his current hot streak.

That’s probably enough to drum up legitimate trade interest, especially when considering his track record. The right-hander has a 2.96 ERA and 233 saves in a career that spans more than a decade. From 2020-24, he posted an ERA of 2.74 or better each season, combining for a 2.44 mark with a 31.6% strikeout rate and 5.4% walk rate. This year’s $16MM salary is steep, but there will “only” be $5.333MM of that sum left come deadline day. (As of this writing, it’s $6.795MM.)

As for the 34-year-old Ozuna, he’s having a solid season at the plate but isn’t hitting anywhere near his 2023-24 levels. This year’s .236/.363/.385 slash is 14% better than league-average in the estimation of wRC+, a far cry from the 48% gap between Ozuna and the average MLB hitter in ’23-’24. Ozuna’s bat speed has dipped by 1.5 mph since 2023, per Statcast, dropping him from the 86th percentile of big league hitters to the 73rd. This year’s 42% ground-ball rate is his highest mark since 2019, while his 13.3% homer-to-flyball rate is his lowest since 2021.

Ozuna is also just swinging far, far less than in recent seasons. He offered at nearly 48% of the pitches he saw in 2023-24 but has swung at just 39.4% of the pitches he’s seen so far in 2025. That’s led to a major jump in walk rate, with the slugger sitting on a career-high 16.4% mark, but that selectivity has resulted in a dip in power output — both on a rate basis and in terms of totality.

While Iglesias has been rebuilding trade value as the summer wears on, Ozuna has been doing the opposite. He’s mired in one of the worst slumps of his career, hitting just .161/.254/.250 over his past 143 plate appearances dating back to early June. He’s still walked at a 10.5% clip along the way and has a roughly average strikeout rate (22.4%), but he’s hitting even more grounders in that stretch and has seen his quality of contact decline. Ozuna is making the same $16MM as Iglesias this season.

The only other pure rental on Atlanta’s roster is the 34-year-old Montero. The Braves surprisingly bailed the Astros out of nearly $3MM of Montero’s ill-fated three-year, $34.5MM contract when they acquired him early this season. He’s pitched decently, logging a 3.86 ERA in 28 innings but walking 12.8% of the batters he’s faced since being traded. He’s had better command recently, issuing just four walks to his past 74 hitters faced, however. With Houston on the hook for the majority of this year’s $11.5MM salary, Montero could hold appeal to teams looking for affordable bullpen help but unwilling to sacrifice top-end prospects to acquire it.

Other clubs will surely try to test the Braves’ resolve when it comes to dealing players controlled beyond the current season. Catcher Sean Murphy has been oft-speculated as a possible trade candidate thanks to the emergence of rookie catcher Drake Baldwin, though Ken Rosenthal of The Athletic recently reported that any such trade is likelier to occur in the offseason. Murphy is signed through 2028 and will be paid $15MM in each of the next three seasons.

Atlanta also has a pair of quality relievers with limited club control remaining in lefty Aaron Bummer (signed for next year at $9.5MM) and righty Pierce Johnson ($7MM club option for 2026). Both are having very strong seasons and will draw interest. Relievers are notoriously volatile, which could tempt Atlanta if another club presents a compelling offer. David O’Brien of The Athletic wrote this morning that the Braves could listen on Johnson, who has a 2.76 ERA, a 27.9% strikeout rate, a 7% walk rate and a 39% grounder rate in 32 2/3 innings. He’s picked up six holds and a save on the season.

There are perhaps larger-scale decisions coming down the pipe with regard to Albies — a former All-Star and Silver Slugger winner who’s batting just .221/.292/.320 in 391 plate appearances. His incredibly affordable club options for the 2026-27 seasons — $7MM apiece — make him a compelling rebound/change-of-scenery candidate.

It’d be tough for the Braves to decline his 2026 option, as it comes with a hearty $4MM buyout, rendering Albies a net $3MM decision. Even if the Braves hope to move on, it’s easy to imagine another club being interested in buying low at that price on what would be Albies’ age-29 and age-30 seasons. MLBTR readers were recently split nearly evenly in a poll on Albies’ future, with 54% saying the Braves should hold and hope for a rebound while 46% indicated that they should trade him, either now or in the offseason.

Pirates Trade Hunter Stratton To Braves

By and | at

The Braves acquired right-handed reliever Hunter Stratton from the Pirates in exchange for minor league outfielder Titus Dumitru and cash, the teams announced Tuesday. Pittsburgh had designated Stratton for assignment last week. Atlanta transferred Chris Sale to the 60-day IL to open a 40-man roster spot for Stratton, who has been optioned to Triple-A Gwinnett.

Stratton, 28, has an unsightly 23.63 earned run average in the majors this year. However, that has come in a tiny sample of 2 2/3 innings. Over the 2023 and 2024 seasons, he had a combined 3.26 ERA in 49 2/3 innings. His 21% strikeout rate and 41% ground ball rate were both around average while his 4.9% walk rate was quite strong.

Though his major league ERA is through the roof this year, his minor league work has largely been in line with his pre-2025 results. In 24 2/3 Triple-A innings this year, he has a 3.65 ERA, 23.8% strikeout rate, 7.9% walk rate and 50% ground ball rate. He still has a full slate of options, though is burning through the first of those here in 2025.

For a pitcher with solid results and roster flexibility, it was a bit surprising that the Pirates gave up on him. But unsurprisingly, there has been enough interest that Atlanta has forfeited a prospect in order to skip the waiver line and add some bullpen depth.

Dumitru, 22, was selected by Atlanta in the 16th-round of last year’s draft. He played at the Single-A level last year and has been at High-A this year. Put together, he has played in 91 professional games with a .227/.314/.324 line and 97 wRC+.

Sale was placed on the 15-day IL a little over a week ago due to a rib cage fracture. The club didn’t provide many details about his expected absence at that time, but it seemed fair to expect he wouldn’t be back anytime soon. Today’s transfer confirms that the club doesn’t expect him back until mid-August at the earliest.

For now, Atlanta is operating with a rotation consisting of Spencer Strider, Spencer Schwellenbach, Grant Holmes, Bryce Elder and Didier Fuentes. Adding to that group would be a priority for the club if they plan on being deadline buyers. President of baseball operations Alex Anthopoulos is hoping to bolster the club rather than subtract from it but they are currently in a tough spot, 7.5 games back of a playoff spot. They have some time to climb but doing so without Sale, Reynaldo López and AJ Smith-Shawver will be a challenge. On the other hand, if they hang in there, it’s possible Sale and López could be back later in the year.

Photo courtesy of Michael McLoone, Imagn Images

MLBTR Podcast: The Braves Say They Won’t Sell, Jeimer Candelario DFA’d, And Injured D-Backs

By | at

The latest episode of the MLB Trade Rumors Podcast is now live on Spotify, Apple Podcasts, and wherever you get your podcasts! Make sure you subscribe as well! You can also use the player at this link to listen, if you don’t use Spotify or Apple for podcasts.

This week, host Darragh McDonald is joined by Anthony Franco of MLB Trade Rumors to discuss…

Plus, we answer your questions, including…

  • Matthew Boyd has already surpassed his highest innings total since 2019. How far do the Cubs push him over the remainder of the season? (32:05)
  • The Padres and Royals have pitching they could trade but should they? (38:20)
  • The Reds don’t have long-term answers at first base, third base, left field, right field or designated hitter. Is there a path to bring in players from outside the organization? (45:40)

Check out our past episodes!

The podcast intro and outro song “So Long” is provided courtesy of the band Showoff.  Check out their Facebook page here!

Photo courtesy of Robert Edwards, Imagn Images

Braves Place Chris Sale On 15-Day IL With Ribcage Fracture

By | at

The Braves announced this afternoon that they’ve placed southpaw Chris Sale on the 15-day injured list with what the club has termed a fractured left ribcage. The club recalled left-hander Austin Cox in a corresponding move. As noted by David O’Brien of The Athletic, Sale was injured on Wednesday night when he made a diving play to stop a grounder off the bat of Juan Soto.

It’s a brutal blow for Atlanta to be dealt, particularly following a banner week that saw them sweep the then-division leading Mets and get within five games of an NL Wild Card spot. They’ve won seven of their last ten games, but if they’re going to keep that momentum going in a bid to get back over .500 and more firmly return to playoff contention they’ll now need to do so without Sale for the time being. The reigning NL Cy Young award winner, Sale has built on his brilliant 2024 season with a 2025 campaign that’s been nearly as good. Across 15 starts this year, the 36-year-old has pitched to a brilliant 2.52 ERA with a 2.65 FIP across 89 1/3 innings of work.

He’s struck out a phenomenal 30.8% of his opponents while walking just 7.0%. Those excellent peripherals have left him with a 2.96 SIERA, making him one of just seven qualified starters in baseball this year with a figure under three. Only Logan Webb and Paul Skenes are having better seasons by measure of ERA, and Sale is doing all of that despite terrible batted ball luck: his .329 BABIP allowed is the fourth-highest figure among qualified starters in the majors this year. It’s been another banner year for the southpaw, who has looked rejuvenated in Atlanta after injury-marred seasons with the Red Sox from 2019 to 2023.

Unfortunately, that resurgence is now put on hold by another significant injury. Sale’s timetable for a return to action is not yet known at this point, but it’s worth noting that a stress fracture in Sale’s right ribs cost him the first half of the 2022 season. After being sidelined in mid-March by the injury, Sale did not return to the mound until early July. A similar timeline would put the remainder of the southpaw’s 2025 campaign in danger, but it’s important to note that it’s unclear if Sale’s current rib cage fracture is as severe as the rib issue he dealt with in 2022.

However long the ace’s absence ultimately ends up being, it leaves Atlanta with a rotation mix that’s stretched very thin. The team is already without Reynaldo Lopez for the foreseeable future after he underwent shoulder surgery earlier this year, and AJ Smith-Shawver is done for the season after undergoing Tommy John surgery. Spencer Schwellenbach and Spencer Strider will attempt to hold things down at the front of the rotation in Sale’s absence, while Grant Holmes and Bryce Elder will look to handle mid-rotation duties. Rookie Didier Fuentes currently holds the fifth starter job after making a spot start against the Marlins yesterday, but another starer like Hurston Waldrep, Davis Daniel, or even Ian Anderson could also be called upon to help round out the rotation mix.

Anthopoulos On Trading Chris Sale: “Will Not Happen”

By | at

The Braves enter play tonight seven games below .500. They’re 12 back of the Mets in the division and 6.5 out in the Wild Card race with five teams to jump. They’ve got their work cut out for them in getting to October for an eighth straight season, but that remains the focus for the front office.

President of baseball operations Alex Anthopoulos spoke with Nick Cellini and Chris Dimino of 680 The Fan this afternoon. The veteran executive made clear he’s operating with a buyer’s mentality six weeks before the trade deadline. He was even more forceful in pushing back against the idea that they’d consider trading away key players — at least barring a terrible stretch of play in July.

Anthopoulos interrupted a question about other clubs potentially attempting to pry defending Cy Young winner Chris Sale out of Atlanta. “No, zero. I’ve seen the speculation. It’s completely ridiculous to me. We are not selling, especially someone that has club control beyond the current year,” he said. “Will not happen. I never make definitive statements unless I’m going to stick to them. Once you make definitive statements and then you go back on them, you’re a liar and you’re done.

Will. Not. Happen. Bold, italicize it, caps. So much so that I’m trying to make a trade now — it’s very hard to make a trade in June — just to signal to everybody that we will not sell. (If) you get to the end of July and things are completely changed, I guess we would reevaluate, but you’d have to be extreme. We’re built to win. Our expectations are to win. Our expectations are to go for it the entire time.”

It’s not common for an executive to rule out trading a player that definitively. It’s even rarer for them to reverse course after making a public statement to that effect. Skeptics will point to Nationals’ GM Mike Rizzo saying the team was “not trading Juan Soto” less than two months before they did exactly that, but the turn of events required Soto rejecting an intervening $440MM extension proposal. Anthopoulos left the door slightly open to selling if the team’s play over the next month and a half made a postseason run all but impossible. Even in that scenario, it’s not clear that they’d be willing to discuss players who are signed beyond this season.

MLBTR examined the Sale situation in a post for Front Office subscribers last week. He’s playing this year on a $22MM salary and is under control via an $18MM option for one more season. They’ll rubber stamp the option unless he suffers a significant injury in the second half. Sale would command upwards of $30MM annually (for at least two and possibly three years) if he were a free agent. After running into some tough batted ball luck in April, he’s been every bit as dominant as he was last season. Sale had not allowed more than two earned runs in any of his past 10 starts coming into tonight’s game against the Mets. He is through another six scoreless innings at the time of this writing.

Even if the Braves miss the postseason in 2025, they’ll certainly go into next year expecting to contend. Having Sale atop the rotation makes that much more reasonable. At the same time, they’d bypass an opportunity at a massive trade haul this summer. Teams would be willing to give up significant young talent for the ability to control Sale for two postseason runs. The Braves still expect to be in that position themselves. If they remain well below .500 on July 31, however, they’d arguably be leaving significant value on the table as an at best long shot contender for one of Sale’s two remaining control years.

Anthopoulos argued that the next few weeks represent a huge opportunity. They’re currently playing the second game of a three-game set against the Mets. They’ll head to Miami this weekend before squaring off against the Mets (for four) and Phillies (for three) next week. They rearranged their rotation to ensure that Sale is lined up for both New York series rather than starting last weekend against the Rockies and taking on the Marlins in a few days.

They’re far enough behind New York and Philly that it’s difficult to see them winning the NL East, but they could theoretically pull back into the race if they go on a tear over the next two weeks. They’ll also take on St. Louis, one of the teams above them in the Wild Card standings, in their final series before the All-Star Break. While those will be tough sets, they have softer matchups against a few teams toward the bottom of the American League standings (the Angels, Orioles and A’s) in the first two weeks of July.

In the meantime, they’re evidently searching for a short-term boost. In this morning’s radio interview (which Atlanta fans will want to give a full listen), Anthopoulos identified the offense as the team’s biggest disappointment to date. Jon Heyman of The New York Post wrote last week that they were pursuing outfield and shortstop help.

Nick Allen is a Gold Glove-caliber shortstop but isn’t going to provide anything offensively. Left field would be the obvious area to upgrade in the outfield. Neither Alex Verdugo nor Eli White have stepped up since Jurickson Profar’s performance-enhancing drug suspension. The Braves will get Profar back in early July, but he’s coming off a nearly three-month layoff and faces questions about the sustainability of last year’s breakout season. He’s also ineligible for postseason play this year, so the Braves probably want a contingency plan for that position regardless of how Profar performs next month.

Should The Braves Consider Offers On Chris Sale?

By | at

The Braves have continued to underperform as the season nears its three-month mark. They clawed back from their 0-7 start to get above .500 in mid-May -- right as they were about to activate Ronald Acuña Jr. and Spencer Strider from the injured list. Optimism was high. Then came a stretch of 14 losses in 17 contests that dropped them to a season-high 10 games below .500 over the weekend. They're coming off a solid series win in Milwaukee, but they face long odds to climb back into a tough NL playoff race. The division is all but gone, and they're nine games back with six teams to jump in the Wild Card picture.

Atlanta's front office isn't going to sell six weeks in advance of the trade deadline. They've invested a lot and this core's prior successes have earned them as much runway as possible to get hot. Jon Heyman of The New York Post wrote last night that the Braves still view themselves as buyers, highlighting shortstop and the outfield as potential targets.

Still, they're running low on time and coming off their worst stretch of the season. The back half of the lineup, late-inning relief mix, and starting pitching depth are all issues. They'll need a significant turnaround in the next 4-6 weeks to avoid selling some short-term pieces. Marcell Ozuna would be an obvious candidate as a rental bat who is raking for a third consecutive season. They could try to offload impending free agent reliever Raisel Iglesias, who has put himself on shaky ground by struggling with the longball. The tougher question is whether the front office should move any key players who are controllable beyond this year -- with Chris Sale leading the way as the team's top option.

Unlock Subscriber-Exclusive Articles Like This One With a Trade Rumors Front Office Subscription

BENEFITS
  • Access weekly subscriber-only articles by Tim Dierkes, Steve Adams, and Anthony Franco.
  • Join exclusive weekly live chats with Anthony.
  • Remove ads and support our writers.
  • Access GM-caliber tools like our MLB Contract Tracker

Looking Ahead To Club Options: NL East

By | at

MLBTR continues our division by division look at next year’s team/mutual option class with the NL East. Only three teams in the division have such options, though Atlanta’s group of decisions involve some of the more notable players in the class.

Previous installments: player options/opt-outs, NL West, AL West, NL Central, AL Central

Atlanta Braves

This is the final guaranteed season of the $35MM extension which Albies signed early in 2019. The deal was widely considered a massively team-friendly contract the day it happened, and that has proven to be the case. Albies has made a pair of All-Star teams, won two Silver Slugger Awards, and twice found his name on MVP ballots over the course of the deal.

There’s no intrigue to this one. The Braves will exercise the option, which ends up being a $3MM investment after factoring in the $4MM buyout. There will be another $7MM club option (with no buyout) for 2027 that will probably be a similarly easy call. Albies’ offense has declined over the past two seasons, as he’s hitting just .246/.300/.398 in 553 plate appearances since the start of 2024. The $3MM difference between the option price and the buyout is low-end utility player money, though. Even if the Braves start to question whether Albies remains the answer at second base, there’d be surplus trade value.

Atlanta signed Arcia to a three-year, $7.3MM extension on the eve of the 2023 season. It looked like an odd move at the time, an unnecessary multi-year commitment for a likely utility infielder. Then Arcia broke out with an All-Star season while replacing Dansby Swanson as Atlanta’s everyday shortstop. The contract looked like a major coup for the front office.

Things have swung back in the opposite direction over the past year-plus. Arcia’s bat cratered last year, as he turned in a .218/.271/.354 line over 602 plate appearances. While the Braves stuck with him as their starting shortstop, he’s lost that role with a dismal start to the ’25 season. Arcia has hit .200 with eight strikeouts, one walk, and one extra-base hit (a double) through 31 trips. Nick Allen jumped him on the depth chart and has started the past five games. Arcia wouldn’t need to do much to convince the Braves to exercise an option that amounts to a $1MM decision, but he’s no longer a lock to even stick on the roster all season.

Johnson dominated over 24 appearances after being acquired from the Rockies at the 2023 deadline. The righty would have been one of the better setup men in the following free agent class, but the Braves signed him to a two-year extension with a $14.25MM guarantee to keep him off the market. He has made consecutive $7MM salaries and has a matching club option with a $250K buyout for next season.

It has worked out nicely. Johnson fired 56 1/3 innings of 3.67 ERA ball with a strong 28.4% strikeout rate last year. He has punched out 10 while allowing four runs through 9 1/3 frames to begin this season. His whiffs are slightly down, while opponents are making more hard contact than they did a season ago. Those are worth monitoring, but Johnson’s overall body of work in Atlanta consists of a 2.89 earned run average with 109 strikeouts over 89 1/3 innings. As of now, a $6.75MM price point seems like solid value.

Sale’s first season in Atlanta was brilliant. He posted an MLB-best 2.38 ERA while leading the National League with 225 strikeouts. He won his first career Cy Young award after finishing in the top six on seven occasions earlier in his career. He reestablished himself as an ace following some injury-plagued years. The trade in which he was acquired from the Red Sox for struggling second baseman Vaughn Grissom has been a steal.

The left-hander’s uneven start to 2025 has contributed to the Braves’ mediocre April. Sale has allowed 5.40 earned runs per nine through his first six outings. They’ve gone 3-3 in those contests. It’s largely the product of an inflated .400 batting average on balls in play against him. Sale’s 27.3% strikeout rate is down nearly five percentage points relative to last season, but it remains a well above-average mark for a starting pitcher. He’s getting whiffs on 12.9% of his offerings. His slider has been as lethal as ever. Opponents have feasted on his fastball so far, but there’s no dramatic change in velocity or spin. While the poor start has probably tanked his chance of repeating as the Cy Young winner, the $18MM option still seems like an easy “yes” for the front office.

Miami Marlins

  • None

New York Mets

Over the weekend, Raley reportedly agreed to terms with the Mets on a one-year deal with a club option. The signing has not been finalized, nor has the money been reported. Raley is working back from last May’s Tommy John surgery.

The Mets also re-signed Smith on a one-year deal with an option after TJS — a July operation, in his case. He’s making $1MM for what will probably be a completely lost season. The Mets get an affordable $2MM option for next season that they’re likely to exercise so long as Smith doesn’t suffer a setback. If they do pick it up, he could earn another $750K based on his appearance total next season. Smith would make $50K apiece at 30, 35, and 40 appearances; $75K for 45 and 50 games; $100K at 55 and 60 appearances; and $125K each for 65 and 70 games. He owns a 3.48 ERA over parts of six seasons as a quality middle reliever for New York.

Philadelphia Phillies

Alvarado signed for two years and $18.55MM in new money on a deal covering the 2024-25 seasons. He has made $9MM salaries in each of the past two years and has a matching option with a $500K buyout. That’s a little below the market rate for high-leverage relievers, which Alvarado has proven himself to be.

Over parts of five seasons with the Phils, the lefty carries a 3.34 earned run average. Bouts of wildness have led to some inconsistency, but he’s shown the ability to miss bats at plus rates while throwing as hard as any left-hander in the sport. Alvarado’s 24.4% strikeout rate last season was oddly pedestrian, but he’s fanned nearly 30% of batters faced in his career.

He has been back at peak form to begin this season. He has punched out 18 of 56 hitters (32.1%) while allowing only three runs through 13 2/3 innings. Alvarado has collected five saves and a pair of holds without blowing a lead, and he’s operating with career-best control (3.6% walk rate). It’s tough to envision him continuing to throw this many strikes — he walked more than 10% of opponents in seven consecutive years leading up to this one — but he’s the Phils’ most trusted reliever right now. This is tending towards an easy pickup.

Shortly before Opening Day last year, Strahm preemptively signed a one-year extension covering the 2025 season. The lefty is making $7.5MM this year and has a club/vesting option for next season. It begins as a $4.5MM team option. The price would jump by $1MM apiece if he reaches 40, 50 and 60 innings pitched this year. If he hits 60 innings and passes a postseason physical, it vests at $7.5MM. It’s a straight vesting option, not one with an opt-out, so Strahm would return on a guaranteed deal if it triggers.

That’s a result with which the Phillies would probably be happy. Strahm turned in an excellent ’24 campaign, working to a 1.87 ERA while striking out a third of opposing hitters over 66 appearances. He has fanned 15 through his first 11 2/3 frames this year. Strahm has surrendered five runs, four earned, on 11 hits and four walks. His 91.8 MPH average four-seam fastball is down from last season’s 93.4 mark, which is a little alarming, but the results have been solid and he remains one of the more reliable setup options for skipper Rob Thomson.

Washington Nationals

  • None

NL East Notes: Sale, Montas, Wood

By | at

Braves left-hander Chris Sale just had a tremendous bounceback season. He made 29 starts with a 2.38 earned run average, earning a National League Cy Young award. He was largely injured and/or ineffective from 2019 to 2023, which had him pondering retirement.

“I thought that it was gonna be my last year,” Sale said to the Baseball Isn’t Boring podcast about where he was at before getting traded to Atlanta. “So I went into that offseason on a mission like ’one more year left.’… ’cause in my mind, I wasn’t walking away from baseball. I was walking away from getting hurt.”

The Red Sox traded Sale to Atlanta for Vaughn Grissom in December of 2023. At the time, as mentioned, he had been battling significant injuries for five years. Tommy John surgery in 2020 was the big one but Sale also had a stress reaction in his ribs, a fractured finger, a broken wrist suffered in a bicycle accident and a stress reaction in his shoulder blade over that span. He had a 4.16 ERA in 298 1/3 innings over those five seasons.

2024 was the final year of his extension with the Red Sox and the mounting injuries apparently had him looking towards hanging up his spikes. But he was traded to Atlanta, signed an extension that covered 2024 and 2025 with a club option for 2026, and then went on to have an excellent season in 2024. It makes for an interesting “what if” but Sale is clearly in a better spot now. The injury bug hasn’t left him entirely alone, however. He missed the final two weeks of 2024 due to back spasms and was also left off Atlanta’s postseason roster. 2024 was still a big improvement over prior years but time will tell if he can keep the good health going into his age-36 season.

Some more spring training tidbits from the NL East…

  • It was reported earlier this week that Mets righty Frankie Montas has a lat strain and will be shut down for six to eight weeks. The righty is apparently a bit more optimistic than his club, however. He told members of the media today, including Anthony DiComo of MLB.com, that he’s already feeling better from his platelet-rich plasma injection and expects to be throwing again in four to six weeks. That’s still a notable period of time but it’s a bit less dire than the other timeline. He had a 4.84 ERA last year and then signed a two-year, $34MM deal with the Mets this winter. He will have the chance to opt out after the first year, though returning healthy and productive will be important if he is to consider that possibility. For now, the Mets’ rotation mix includes Sean Manaea, Kodai Senga, David Peterson, Clay Holmes, Paul Blackburn, Griffin Canning and Tylor Megill.
  • Nationals outfielder James Wood has some quad tendinitis, per Andrew Golden of The Washington Post. It doesn’t bother him when he hits, so he’s been able to take batting practice but has skipped some defensive drills. Per Mark Zuckerman of MASNsports.com, Wood says he has “zero” concern but the club did send him for an MRI, which showed no structural damage. With still over a month before Opening Day, there’s plenty of time to get things in order, with Wood and the Nats both surely hoping for a clean bill of health by then. Now just 22 years old, Wood hit .264/.354/.427 in his major league debut last year and is slated to be a big part of the club’s future.

Chris Sale Wins National League Cy Young Award

By | at

Braves left-hander Chris Sale has been named the National League Cy Young Award winner for 2024, per an announcement from the Baseball Writers Association of America. Zack Wheeler of the Phillies finished in second place with Paul Skenes of the Pirates in third place.

The award is the final cherry on top of a remarkable comeback season for Sale. He had a run from 2010 to 2018 of being one of the best pitchers in the majors, but struggled in 2019 and then was in the injury wilderness for quite a while. Due to various ailments, including Tommy John surgery, he only pitched about 150 innings total from 2020 to 2023.

The Red Sox flipped him to Atlanta almost a year ago, in December of 2023. The move was seen as risky at the time, as Sale was going into his age-35 season and was several years removed from his prime.

On top of that, Atlanta sent Vaughn Grissom to Boston in the deal, a notable prospect who still had years and years of cheap control. In return, they were getting just one year of Sale, though they did sign him to an extension that covered 2024 and 2025 with a club option for 2026. That extended their window of control over him, but at a fairly hefty price point: $38MM for the two guaranteed years plus $18MM for the option.

But so far, the deal has been incredibly lopsided in favor of Atlanta. Grissom was injured for much of 2024 and didn’t perform well while healthy. For Atlanta, most of their key contributors got hurt this year while Sale ironically stayed healthy, in spite of his recent track record.

Sale finished the season having made 29 starts and thrown 177 2/3 innings, allowing 2.38 earned runs per nine. He struck out 32.1% of batters faced, only gave out walks 5.6% of the time and got grounders on 44.8% of balls in play. He won the pitching triple crown by leading the National League in ERA, wins and strikeouts. His tally of 6.4 wins above replacement from FanGraphs was easily the most in the majors this year, with Tarik Skubal of the Tigers second at 5.9 fWAR.

Despite his previous dominance, this is actually Sale’s first time taking home the hardware. Per MLB’s Sarah Langs on X, Sale is the first pitcher to finish top five in Cy Young voting in five straight years, fall outside the top five for five straight years immediately after, followed by a return to the top five. He is also (X links from Langs) the first pitcher to have six previous top five finishes and later win the award, in addition to being one of the five oldest pitchers to win for the first time.

Sale got 26 of the first place votes (full vote tallies from the BBWAA), with the other four going to Wheeler, who logged exactly 200 innings over 32 starts with a 2.57 ERA. Skenes already won Rookie of the Year award earlier this week but this further cements what an amazing season he had. Other pitchers getting votes were Dylan Cease, Shota Imanaga, Logan Webb, Michael King, Hunter Greene, Ryan Helsley, Cristopher Sánchez, Reynaldo López, Sean Manaea and Aaron Nola.

Gold Glove Winners Announced

By | at

Major League Baseball announced the Gold Glove winners tonight, as selected by a group of managers, coaches, and statistical analysis.  Twenty-five percent of the selection total was determined by SABR’s Defensive Index metrics, while the other 75 percent was determined by votes from all 30 managers and up to six coaches from each team.  The utility Gold Glove was determined in a separate fashion, via a defensive formula calculated by SABR and Rawlings.

National League winners….

American League winners….

Show all

MLB Trade Rumors is not affiliated with Major League Baseball, MLB or MLB.com

Do not Sell or Share My Personal Information

hide arrows scroll to top